TLY012 with PD-1 inhibition promotes tumor regression in pancreatic adenocarcinoma

Wafik S. El-Deiry posted on LinkedIn:

“Pleased to share preprint by Dr. Anna Louie and colleagues from eldeiry lab at The Warren Alpert Medical School of Brown University.

TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma.”

Read Further.
Source: Wafik S. El-Deiry/LinkedIn

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget.

Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.

Anna Louie is an Associate Professor in the Department of Pathology and Laboratory Medicine at The Warren Alpert Medical School of Brown University. She is involved in both teaching and research in pathology, focusing on improving diagnostic practices and understanding disease mechanisms.